Riskpilot← Back to searchSign inGet full accessVaccination Växjö AB
ABActiveOrg 5569465189Honnörsgatan 7General medical practice activities · NACE 8621Est. 20131 employees
Revenue 2024
SEK 8,5M
+9% vs 2023
EBITDA margin
22.0%
+20% vs 2023
Equity ratio
62.8%
Financial strength
Net profit 2024
SEK 1,3M
+22% vs 2023
| Revenue | SEK 8,5M | +9% |
| EBITDA | SEK 1,9M | +20% |
| Net profit | SEK 1,3M | +22% |
| Total assets | SEK 6,9M | +21% |
| Equity | SEK 4,3M | +30% |
| Employees | 1 | — |
Legal name
Vaccination Växjö AB
Org number
5569465189
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
25 oktober 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Vaccinationsverksamhet.
Address
Honnörsgatan 7
Email
asa.kaberg@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 646 | 5 214 | 7 729 | 7 790 | 8 519 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 380 | 791 | 1 466 | 1 560 | 1 878 |
| Depreciation & amort. | −28 | −0 | −0 | −2 | −6 |
| EBIT | 352 | 791 | 1 466 | 1 558 | 1 872 |
| Net financials | −8 | −3 | −22 | — | 16 |
| Profit before tax | 351 | 678 | 1 178 | 1 319 | 1 612 |
| Tax | −82 | −149 | −255 | −290 | −357 |
| Net profit | 269 | 529 | 923 | 1 029 | 1 255 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 987 | 3 367 | 4 786 | 5 694 | 6 888 |
| Equity | 1 591 | 1 870 | 2 543 | 3 322 | 4 327 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 246 | 237 | 716 | 606 | 519 |
| Total debt | 246 | 237 | 716 | 606 | 519 |
EBITDA margin
22.0%
This company
15.8%
Market median
+39% vs market
20202024
Equity ratio
62.8%
This company
38.2%
Market median
+64% vs market
20202024
Return on equity
29.0%
This company
18.4%
Market median
+58% vs market
20202024
Net profit margin
14.7%
This company
8.1%
Market median
+81% vs market
20202024
Asset turnover
1.24×
This company
1.12×
Market median
+11% vs market
20202024
Debt / equity
0.59×
This company
0.62×
Market median
+5% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MD | Audit | 2022 |
ÅH Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Vaccination Växjö AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Daniel Andersson | Audit | 0 companies |
| Åsa Helena Klüft Kåberg | Chief Executive Officer | 0 companies |
| Bertil Olof Klüft | Deputy Board Member | 0 companies |
| Björn Johan Stefan Kåberg | Board of Directors | 0 companies |